Skip to content

Upper Limb Movement

All ONWARD® Medical therapies are investigational and not available for commercial use.

Discover Our Therapy

  • ARC Therapy is targeted stimulation of the spinal cord designed to restore movement and other critical functions after spinal cord injury, such as blood pressure stability and bladder control.

    These benefits have been observed in published pre-clinical and human feasibility studies.


    Clinical results may vary.
    Investigational and not available for commercial use.

    Watch how it works

External Platform

  • Investigational, external spinal cord stimulation platform to non-invasively deliver ARCEX® Therapy to the spinal cord.

    The US FDA granted the ARCEX platform Breakthrough Device Designations for upper and lower limb function, bladder control, regulation of blood pressure, and alleviation of spasticity in people with spinal cord injury.

    In 2024, we submitted an application to the FDA for clearance to market the ARCEX® System in the US for improvement in upper limb function. We plan to submit an application in Europe in 2025.

    Learn more

Discover The Potential Benefits

ARCEX is designed to help people with spinal cord injury regain more control over their day.

This is a example

Arm and hand movement

Dexterity and finger control

Sensation

“When we talk about 10% more function, we think about how important that is in terms of being able to live a life. That little bit more independence allows you to do so much more.”

Jessie Owen

ARCEX Therapy trial participant

Read Our Publications

    Learn more

    Read The Evidence

    The results from our Up-LIFT pivotal trial were published in Nature Medicine, one of the world’s preeminent scientific journals.

    The Up-LIFT study evaluated the safety and effectiveness of non-invasive electrical spinal cord stimulation (ARCEX Therapy) to improve upper limb mobility in people with chronic incomplete tetraplegia. The clinical study enrolled 65 people at 14 leading SCI centers in the US, Europe, and Canada.

    Highlights* include:
    Primary safety and effectiveness endpoints met.
    90% of participants improved strength or function of their upper limbs.
    87% of participants reported improvement in quality of life.
    Improvement was demonstrated in participants up to 34 years post-injury.

    Learn more

    Contact Us

    Please fill out the form
    to contact us or
    to receive updates

    Complete form
    All ONWARD® Medical devices and therapies referenced here, including but not limited to ARCIM®, ARCEX®, ARCBCI™, and ARC Therapy™, alone or in combination with a brain-computer interface (BCI), are investigational and not available for commercial use.

    *Moritz, Chet, et al. “Non-invasive spinal cord stimulation for arm and hand function in chronic tetraplegia: a safety and efficacy trial.” Nature Medicine. 2024.